were not found in Ts cells from ITP patients. Furthermore, Inducible T-cell costimulatory (ICOS) expression on the Ts cell surface after activation was decreased whereas programmed death 1 and interleukin 10 expression was not changed in ITP patients compared with those of controls. In summary, the down-regulated quantity and function of Ts cells in active patients indicated that a Ts defect was involved in ITP. Moreover, decreased ICOS expression and the loss of the ability to regulate co-stimulator expression on antigen-presenting cells partly explained the defective Ts-mediated suppression.
Summary
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Immune thrombocytopenia (ITP) is an autoimmune disease that is characterized by low platelet counts due to increased platelet destruction and insufficient platelet production (Semple, 2002) . Like the majority of autoimmune diseases, multiple abnormalities in immune systems have been implicated in ITP pathogenesis. Among them, defective CD4 + CD25 + FoxP3 + regulatory T cells and regulatory B cells; decreased plasma interleukin (IL)10, transforming growth factor (TGF) B1 and IL35 concentrations; and reduced inhibitory Fcc receptor IIb levels on monocytes in ITP patients suggest that the loss of immune tolerance plays an important role in ITP (Liu et al, 2007; Yang et al, 2014; Andersson, et al, 2002 , Liu et al, 2011 Li et al, 2012) . CD28 is a key co-stimulator that can induce activation and proliferation of T cells; thus, down-regulation in CD28 expression may lead to T cell dysfunction. Previous studies demonstrated that CD8 + CD28 À T suppressor (Ts) cells could inhibit T cell proliferation as well as the cytotoxic function of T lymphocytes (Fenoglio et al, 2008) . The suppressive mechanism involves: (i) Ts cells can upregulate LILRB4 (also termed ILT3) and LILRB2 (also termed ILT4) expressions on antigen presenting cells (APCs). These two inhibitory molecular display long cytoplasmic tails containing immunoreceptor tyrosine-based inhibitory motifs (ITIMs) and inhibit cell activation by recruiting protein tyrosine phosphatase SHP-1, thus they can render tolerogenic APC and block their co-stimulated capacity (Ravetch & Lanier, 2000) . The tolerized APC, in turn, can anergize effector T cells, further inhibiting the activation and amplification of T cells (Cortesini et al, 2001) , (ii) Ts cells can inhibit T cell activation by secreting the suppressive cytokine IL10 (Ceeraz et al, 2013) . Regarding the vital roles of the control of self-reactive T cells and sustaining immune tolerance, Ts cell abnormalities are related to cancer immune escape, graft rejection and autoimmunity (Lin et al, 2009; Mikulkova et al, 2010; Scarsi et al, 2011; Chen et al, 2014; . Recently, Ma et al (2015) . However, the exact role of Ts cells in ITP patients is still unknown. In the present study, we investigated the ex vivo phenotypic and functional characteristics of Ts in ITP and tried to uncover the reasons for these defects.
Materials and methods

Patients
A total of 66 ITP patients and 58 age-and gender-matched healthy donors were enrolled in this study. The diagnosis of ITP was based on the recently reported criteria (Rodeghiero et al, 2009 ). The patients were divided into three subsets to detect the number, function and costimulatory expression of Ts cells. As the flow cytometry analysis needed less than 500 ll peripheral blood (PB), we used residual samples that were available following clinical blood routine examination of outpatients. Thus, we could collect untreated patients. However, because a large blood sample was needed to ensure sufficient CD8 + Ts cells, we could only use inpatients who had been transferred from another local hospital. Thus, it was difficult to enrol untreated patients. The clinical parameters of the ITP patients are summarized in Tables I-III. Patients with a platelet count less than 100 9 10 9 /l were defined as active ITP and a platelet count greater than 100 9 10 9 /l was defined as ITP in remission. Patients who did not receive glucocorticoids (GCs), intravenous immune globulin or immunosuppressants were categorized as untreated ITP. Our research was approved by the hospital based ethics committee, and written informed consent was obtained from all participants.
Purification of lymphocyte subpopulations
Peripheral blood mononuclear cells (PBMCs) were separated by density-gradient centrifugation. CD4 + T cells were purified using a commercial CD4 positive selection magnetic activated cell sorting (MACS) isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany Cell surface staining. To assay programmed cell death 1 (PDCD1, also termed PD-1) and inducible T-cell costimulatory (ICOS) expression on the Ts cell membrane, 1 9 10 6 isolated PBMCs were cultured in 1 ml of complete RPMI 1640 medium (containing 10% fetal calf serum, 1% glutamine/penicillin/streptomycin) with or without 5 mg/ml phytohaemagglutinin (PHA) and 5 ng/ml recombinant human (rh)IL2 for 48 h at 37°C, 5% CO 2 . For CD80, CD86, LILRB4 and LILRB2 expression on CD14 + monocytes, 1 9 10 6 CD4 À CD8 À plastic-adherent cells as APCs were co-cultured with 2 9 10 5 Ts cells in 1 ml of complete RPMI 1640 medium and stimulated with 5 mg/ml PHA and 5 ng/ml rhIL2 for 48 h at 37°C, 5% CO 2 . After culture, the cells were collected and surface-stained with the required antibodies for 20 min at room temperature (to detect PDCD1 and ICOS: Percp-cy5.5-CD8, APC-CD28, FITC-ICOS, PE-PDCD1 and the appropriate isotype controls; to detect CD80 and CD86 on monocytes: PE-CD14, APC-CD80, FITC-CD86 and the appropriate isotype controls; to detect LILRB4 and LILRB2 on monocytes: PE-CD14, PE-cy7-LILRB4, APC-LILRB2 and the appropriate isotype controls), then washed twice in wash buffer and fixed for analysis.
Cytokine staining. After activation with 5 mg/ml PHA and 5 ng/ml rhIL2 for 48 h, PBMCs were re-stimulated with 50 ng/ml of phorbol 12-myristate 13-acetate, 1 lg/ml of ionomycin and 10 lg/ml of brefeldin A (Sigma, St Louis, MO, USA) for 5 h at 37°C and 5% CO 2 . The cells were then incubated with Percp-CD8 and FITC-CD28 (Biolegend) at room temperature for 20 min. After incubation, the cells were washed twice with wash buffer and fixed with 4% paraformaldehyde, followed by permeabilization (FACS permeabilizing solution; BD PharMingen, San Jose, CA, USA). The cells were then stained with PE-cy7-IL10 (Biolegend) at room temperature for 45 min, washed twice, and re-suspended with 1% paraformaldehyde for analysis by flow cytometry. Analysis of all samples was conducted using a BD Canto II flow cytometer (BD Biosciences). ) treated with mitomycin C were co-cultured with 3 9 10 5 cells/well autologous responder T cells (CD8 + CD28 + or CD4 + T cells) and 3 9 10 5 mitomycin C-treated APCs in a 24-well plate for 3 days at 37°C with 5% CO 2 in 0Á5 ml of complete RPMI 1640 medium supplemented with 5 mg/ml PHA and 5 ng/ml rhIL2. The responder cells were pulsed with BrdU (R&D Systems, Minneapolis, MN, USA) for 18 h, then harvested and transferred to a 96-well plate (divided into three wells on average) and dried; proliferation was measured according to the manufacturer's instructions. The culture supernatants were stored at À80°C until analysed. Additionally, cell-cell contact dependence was determined by a transwell (TW) assay; 1Á5 9 10 5 mitomycin C-treated Ts cells were co-cultured with 3 9 10 5 CD4 + responder cells and 3 9 10 5 mitomycin C-treated APCs were directly mixed in or physically separated in the TW inserts of 24-well TW plates (0Á4 lm pore size; Corning, Corning, NY, USA). After 72 h, the proliferation of responder cells was analysed by detecting BrdU incorporation.
Ts cell suppression assays
Enzyme-linked immunosorbent assay (ELISA) for cytokines
The concentrations of c-interferon (IFNG), transforming growth factor-b (TGFB1) and IL10 in the cell culture supernatants were measured using an ELISA kit (NeoBioscience Technology, Shenzhen, P. R. China) according to the manufacturer's instructions.
Statistical analysis
Statistical analysis was performed using SPSS 16.0 (SPSS Inc., Chicago, IL, USA). Unless indicated, data were expressed as the meanAEstandard error of the mean (SEM). The percentage of Ts cells in PB among active ITP patients, ITP patients in remission and controls were analysed by one-way analysis of variance. The effects of Ts on proliferation and co-stimulator expression of APCs were determined by the two related samples Wilcoxon signed rank test. All other parameters were analysed using the Mann-Whitney U test. P < 0Á05 was considered significant. 
Results
Decreased
CD28
À CD127 À Ts cells in the CD8 + population was observed in patients with active ITP compared with healthy controls (P = 0Á034, Fig 1B) . Additionally, although the proportion of Ts cells appeared to be elevated in ITP patients in remission, there was no significant difference between patients with active ITP and those in remission (P = 0Á156). Given that an ageindependent increase in CD8 + CD28 À T cells in healthy volunteers has been reported (Bandres et al, 2000; Vallejo, 2005) , we also analysed the association between age and the percentage of CD8 + CD28 À T cells and found a positive correlation in controls (P = 0Á014, Fig 1C) but not in ITP patients (P = 0Á129, Fig 1D) . ITP patients and controls did not differ in age (P = 0Á925). Additionally, the results showed that the frequency of CD8 + CD28 À CD127 À Ts cells in active chronic ITP patients was lower than that of healthy controls (P = 0Á024, Fig 1E) . No correlation was found between Ts cells and gender, platelet count or disease duration. Moreover, Ts from ITP patients were less efficient in suppressing CD4 + effector T cells proliferation compared with
Impairment of Ts-mediated immunosuppression in ITP patients
that from controls at a ratio 1:2 (P = 0Á027). Although a similar tendency was found at ratio 1:4, it did not reach significance (P = 0Á053). The results are summarized in Fig 2A. Correspondingly, Ts cells from controls inhibited autologous CD8 + CD28 + effector cells proliferation at both 1:2 and 1:4 ratios (P < 0Á001 and P < 0Á001, respectively), whereas Ts cells from ITP patients only inhibited CD8 + CD28 + effector cells proliferation at a 1:2 ratio (P = 0Á001) (Fig 2B) . Physiologically, Ts cells suppress the proliferation of autoreactive T cells through contact-dependent mechanisms or inhibitory cytokine secretion. To find the reasons for the impairment of Ts-mediated immunosuppression in ITP patients, we conducted TW experiments. Due to the limitation of Ts availablity, we used CD4 + T cells as effector cells in the TW and corresponding co-culture experiments. The results demonstrated that the inhibitory efficiency was lower in the TW group compared with the co-culture group in controls (P = 0Á005), and there was no difference between them in ITP patients (P = 0Á953). Additionally, the suppressive efficiency did not differ in the TW group between ITP patients and controls (P = 0Á531) (Fig 2C) .
Ts-mediated inhibition of IFNG production may be impaired in ITP patients
The T-cell subset skews to Th1 polarization, which is related to the aetiology and disease status of ITP (Semple et al, 1996; Ogawara et al, 2003) . Thus, as the representative cytokine in the Th1 immune response, IFNG concentrations in the co-culture of Ts and CD4 + T cells experiments were measured to assess Ts-mediated inhibition of IFNG production. As shown in Fig 3, IFNG secretion in the culture supernatants of the 1:2 group was significantly inhibited compared with the 1:4 and 0:1 group in controls (P = 0Á028 and P = 0Á021, respectively), and no discrepancy was found among the three groups in ITP patients.
IL10 is a critical mediator for Ts immunosuppression
We also investigated IL10 and TGFB1 expression in the supernatants of Ts cells and CD4 + T cells co-culture experiments. IL10 secretion was enhanced by Ts cells in a dosedependent way in controls, whereas IL10 secretion in ITP patients and TGFB1 secretion both in ITP patients and controls did not differ among the 0:1, 1:4 and 1:2 groups (Fig 3) . Additionally, TGFB1 concentrations in the 1:4 and 0:1 groups from controls were higher than that from ITP patients (P = 0Á008 and P = 0Á028, respectively). We also investigated IL10 secretion in CD8 + CD28 À T cells using FACS; however, no difference in the percentage of IL10 + cells in the CD8 + CD28 À Ts cell population between ITP patients and controls was found (P = 0Á434). Table II . 
Impaired regulatory potential of Ts cells on APCs in ITP patients
Cell to cell direct contact mediated APCs function inhibition is a main mechanism for Ts immunosuppression (Chang et al, 2002) . To try to explain the impaired Ts immunosuppression in ITP patients, we investigated CD80, CD86, LILRB4 and LILRB2 expression on APCs after co-culture with Ts cells. Ts cells from normal controls enhanced LILRB4 and LILRB2 expression but decreased CD80 expression on autologous CD14 + monocytes (P = 0Á005, P = 0Á017 and P = 0Á047, respectively; Fig 4) . Interestingly, these regulatory abilities disappeared in ITP patients. Moreover, CD80 expression on CD14 + monocytes without Ts was higher than that of controls (P < 0Á001).
Decreased ICOS expression on Ts from ITP patients
Ts cell to cell direct suppression was impaired in ITP patients, and ICOS and PDCD1 expressions on Ts cells were abnormal in other autoimmune diseases (Ceeraz et al, 2013) ; thus, we examined their expressions on Ts cells with or without activation both in ITP patients and controls. PHA activation in vitro enhanced ICOS and PDCD1 expressions both in active ITP patients and in controls (Fig 5) . ICOS expression on activated Ts from ITP patients was lower than that of normal controls (P = 0Á036; Fig 5) .
Discussion
Although CD8 + Ts cells play a vital role in immune tolerance (Najafian et al, 2003; Filaci et al, 2007) , there are conflicting results regarding their abnormality in autoimmune diseases (Tulunay et al, 2008; Mikulkova et al, 2010; Slowik et al, 2012; Ceeraz et al, 2013; Dai et al, 2013; Yarde et al, 2014) . What is the reason for this contradiction? It may be because CD8 + CD28 À T cells form a heterogeneous population that includes cytotoxic and immunosuppressive T cells. Accordingly, the overall effect of CD8 + CD28 À T cell-mediated immunity depends on the predominance of a particular subset (Strioga et al, 2011) . Therefore, specific markers for the CD8 + CD28 À suppressor subset are badly in need of Table II . APC, antigen presenting cell; LILR, leukocyte immunoglobulin like receptor; ITP, immune thrombocytopenia; Ts, T suppressor. Table III . *P < 0Á05; **P < 0Á01; ICOS, inducible T-cell costimulatory; ITP, immune thrombocytopenia; PDCD1, programmed cell death 1; Ts, T suppressor.
identification. During recent years, several markers, such as CD57 (Chattopadhyay et al, 2009) suggesting that numerical defects in Ts cells might participate in the course of ITP. However, although the percentage of Ts cells seems to be higher in ITP patients in remission, no significant difference was found. This result may be due to the heterogeneity of ITP and the limited sample size. The reason for the decreased number of Ts cells is currently unknown. We speculated that decreased plasma IL10 and TGFB1 concentrations and the impaired immune regulated ability of bone marrow-derived mesenchymal stem cells could, at least, partly explain the reasons (Andersson et al, 2002; Zhang et al, 2014) . Consistent with the literature, we also found a positive correlation between age and the percentage of CD8 + CD28 À Ts cells in controls but not in ITP patients (Bandres et al, 2000; Vallejo, 2005) . This may be because the repetitive stimulation of platelets leads to the aging of the immune system, thus causing an imbalance between immune system age and physical age in patients with ITP. In addition to the quantity of Ts cells, we also compared the inhibitory potential of Ts cells and found the functional defect in ITP patients. It is notable that all of the patients in this function analysis were treated by GCs. Korecka-Polak et al (2016) found that the suppressor properties of human CD8 + CD28 À T cells were not affected by ciclosporin A and rapamycin. Nevertheless, the influence of GCs on Ts cell function is still unknown. It was reported that dexamethasone increased the proportion and improved the function of CD4 + FoxP3 + regulatory T-cells as well as elevated the number of late stage apoptotic CD4 + T cells (Hu et al, 2012; Wang et al, 2015) . Therefore, we speculated that GCs treatment would improve the Ts inhibition ability, which causes a relatively small difference in the Ts inhibition efficiency between ITP patients and controls. In addition, we also found that Ts cells could inhibit CD8 + CD28 + Te proliferation, further decreasing the number of cytotoxic T cells. However, whether impaired Ts cells primarily act on cytotoxic T cells as opposed to antibody production needs to be evaluated in further experiments. What is the reason for the impaired suppressive functions? We investigated the expression of the anti-inflammatory cytokines TGFB1 and IL10 in the co-culture supernatant. Consistent with previous reports, we found IL10, but not TGFB1, secretion was enhanced in a Ts dose-dependent manner, which affirmed the key role of IL10 in CD8 + Ts mediation of suppression function (Filaci et al, 2004 (Filaci et al, , 2007 . Nevertheless, we found no difference of IL10 expression in Ts cells from ITP patients and normal controls, suggesting that inhibitory cytokine secretion was not the reason for the abnormal Ts cell function in ITP patients.
Besides soluble cytokines, we also performed TW experiments to evaluate the role of cell-contact effect in Ts function abnormality, and found that cell-to-cell contact inhibitory ability was impaired in ITP. So is this defect associated with abnormal ability of the Ts cell to induce tolerogenic APCs? In this study, we also found that CD80 was decreased and LILRB4 and LILRB2 were elevated on CD14 + monocytes after co-culture with Ts cells in controls (Liu et al, 1998; Chang et al, 2002; Najafian et al, 2003 
